Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the financing round further strengthen the company’s position as it advances its lead oncolytic adenovirus, THEO-260, a next-generation oncolytic adenovirus, into clinical trials in ovarian cancer.
Lead Product(s): THEO-260
Therapeutic Area: Oncology Product Name: THEO-260
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sound Bioventures
Deal Size: $24.5 million Upfront Cash: Undisclosed
Deal Type: Financing April 17, 2024
Details:
THEO-260 is a new oncolytic virus in development that is intrinsically capable of targeted killing of both cancer cells and cancer associated fibroblasts (CAFs).
Lead Product(s): THEO-260
Therapeutic Area: Oncology Product Name: THEO-260
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The expanded Series A funding will support the progress of internal programmes in ovarian cancer, and a second cancer indication in addition to further advancing the company's unique technology platforms.
Lead Product(s): Oncolytic Viral Therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: M Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series A Financing July 08, 2021
Details:
The financing will be used to progress the company’s Oncolytic viral therapies towards human clinical trials.
Lead Product(s): Oncolytic viral therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Epidarex Capital
Deal Size: $6.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 07, 2021